Patrick Gagnon
Montreal
Education
Masters, economics, Université du Québec à Montréal; Baccalaureate, economics, Université Laval
Summary of Experience
Mr. Gagnon is an economist who specializes in applying econometric methods to health economics and outcomes research (HEOR). His areas of expertise include economic burden assessment; retrospective database and claims analyses; treatment patterns; chart reviews; and survey analyses on topics such as small and medium-sized enterprises. In his recent work, Mr. Gagnon has conducted HEOR analyses for pharmaceutical companies on Alzheimer’s disease, post-traumatic stress disorder (PTSD), attention deficit hyperactivity disorder (ADHD), bipolar disorder, PIK3CA-related overgrowth spectrum, and various types of cancer. His work has been presented at conferences such as the American Society of Hematology, the American Society of Clinical Oncology, and the Academy of Managed Care Pharmacy, and published in peer-reviewed journals such as PLOS One, the Journal of Medical Economics, and Blood.
Selected Publishing
-
Identifying Individuals with Undiagnosed Post-Traumatic Stress Disorder in a Large United States Civilian Population – A Machine Learning Approach
BMC Psychiatry, 2022
2022Gagnon-Sanschagrin P, Schein J, Urganis A, Serra E, Liang Y, Musingarimi P, Cloutier M, Guérin A, Davis L
-
Treatment patterns among children and adolescents with attention-deficit/hyperactivity disorder in the United States - a retrospective claims analysis
BMC Psychiatry, 2022
2022Schein J, Childress A, Adams J, Gagnon-Sanschagrin P, Maitland J, Qu W, Cloutier M, Guérin A
-
Economic burden of attention-deficit/hyperactivity disorder among children and adolescents in the United States: a societal perspective
Journal of Medical Economics, 2022
2022Schein J, Adler LA, Childress A, Cloutier M, Gagnon-Sanschagrin P, Davidson M, Kinkead F, Guerin A, Lefebvre P
-
The Economic Burden of Posttraumatic Stress Disorder in the United States From a Societal Perspective
The Journal of Clinical Psychiatry, 2022
2022Davis LL, Schein J, Cloutier M, Gagnon-Sanschagrin P, Maitland J, Urganus A, Guerin A, Lefebvre P, Houle CR
-
Treatment patterns among adults with attention-deficit/hyperactivity disorder in the United States: a retrospective claims study
Current Medical Research and Opinion, 2021
2021Schein J, Childress A, Adams J, Cloutier M, Gagnon-Sanschagrin P, Maitland J, Bungay R, Guérin A, Lefebvre P
-
Vaso-occlusive crises and costs of sickle cell disease in patients with commercial, Medicaid, and Medicare insurance - the perspective of private and public payers
Journal of Medical Economics, 2020
2020Shah NR, Bhor M, Latremouille-Viau D, Sharma VK, Puckrein GA, Gagnon-Sanschagrin P, Khare A, Singh MK, Serra E, Davidson M, Xu L, Guerin A
-
The Economic Burden of Nocturia on the U.S. Health Care System and Society: A National Health and Nutrition Examination Survey Analysis
Journal of Managed Care & Specialty Pharmacy, 2019
2019Jhaveri J, Gauthier-Loiselle M, Gagnon-Sanschagrin P, Wu EQ
-
Institutionalization risk and costs associated with agitation in Alzheimer's disease
Alzheimer's & Dementia: Translational Research & Clinical Interventions, 2019
2019Cloutier M, Gauthier-Loiselle M, Gagnon-Sanschagrin P, Guerin A, Hartry A, Baker RA, Duffy R, Gwin K, Aigbogun MS
-
Treatment and Monitoring Patterns Among Premenopausal Women with HR+/HER2- Advanced Breast Cancer
Advances in Therapy. 2018 Sep;35(9):1356-1367
2018Dalal AA, Gauthier G, Gagnon-Sanschagrin P, Burne R, Guérin A, Niravath P, Small T
-
Economic Burden of HR+/HER2- Metastatic Breast Cancer Among Adult Premenopausal Women
Advances in Therapy. Mar 20 2018
2018Gauthier G, Gagnon-Sanschagrin P, Guérin A, Burne R, Small T, Niravath P, Dalal AA
-
Dosing Patterns and Economic Burden of Palbociclib Drug Wastage in HR+/HER2- Metastatic Breast Cancer
Advances in Therapy. April 13, 2018
2018Dalal AA, Gagnon-Sanschagrin P, Burne R, Guérin A, Gauthier G, Small T, Niravath P
-
Assessment of costs associated with adverse events in patients with cancer
PloS One. 2018;13(4):e0196007
2018Wong W, Yim YM, Kim A, Cloutier M, Gauthier-Loiselle M, Gagnon-Sanschagrin P, Guérin A
-
Burden of Infections Among Chronic Myeloid Leukemia Patients Receiving Dasatinib or Nilotinib: A Real-World Retrospective Healthcare Claims Study in the United States
Advances in Therapy, 2018 Oct;35(10):1671-1685
2018Seiter K, Latrémouille-Viau D, Guérin A, Ndife B, Habucky K, Tang DH, Pivneva I, Gagnon-Sanschagrin P, Joseph GJ
-
Increased Prevalence of Cancer in Adult Patients With Psoriasis in the United States: A Claims Based Analysis
J Drugs Dermatol. Feb 1 2018;17(2):180-186
2018Kimball AB, Sundaram M, Cloutier M, Gauthier-Loiselle M, Gagnon-Sanschagrin P, Guérin A, Ganguli A
-
Monitoring of Hematologic, Cardiac, and Hepatic Function in Post-Menopausal Women with HR+/HER2- Metastatic Breast Cancer
Advances in Therapy. 2018 Aug;35(8):1251-1264
2018Guérin A, Goldschmidt D, Small T, Gagnon-Sanschagrin P, Romdhani H, Gauthier G, Kelkar S, Wu EQ, Niravath P, Dalal AA
-
A real-world analysis of healthcare costs and relative risk of hyperprolactinemia associated with antipsychotic treatments in the United States
Journal of Medical Economics. 2018 Dec;21(12):1183-1190
2018Cloutier M, Greene M, Touya M, Gagnon-Sanschagrin P, Guérin A
-
Treatment patterns, healthcare resource utilization, and costs in patients with acute myeloid leukemia in commercially insured and Medicare populations
Journal of Medical Economics. 2018 Jun;21(6):556-563
2018Stein EM, Bonifacio G, Latremouille-Viau D, Guerin A, Shi S, Gagnon-Sanschagrin P, Briggs O, Joseph GJ
-
Adverse Medical Conditions Across Treatment Options in Patients With Psoriasis: A Claims-Based Analysis
Journal of Drugs in Dermatology, 2018
2018Wu J, Armstrong A, Singh R, Cloutier M, Gauthier-Loiselle M, Gagnon-Sanschagrin P, Arikan D, Fleischer A, Guérin A, Ganguli A
-
Health care resource utilization and costs in patients with chronic myeloid leukemia with better adherence to tyrosine kinase inhibitors and increased molecular monitoring frequency
Journal of Managed Care and Specialty Pharmacy. 2017;23(2):214-224
2017Latremouille-Viau D, Guerin A, Gagnon-Sanschagrin P, Dea K, Cohen BG, Joseph GJ
-
Treatment patterns and healthcare costs among newly-diagnosed patients with chronic myeloid leukemia receiving dasatinib or nilotinib as first-line therapy in the United States
Journal of Medical Economics. Jan 2017;20(1):63-71
2017Latremouille-Viau D, Guerin A, Nitulescu R, Gagnon PS, Joseph GJ, Chen L.
-
Treatment patterns and healthcare costs among newly-diagnosed patients with chronic myeloid leukemia(1)
Journal of Medical Economics. Jan 2017;20(1):63-71
2017Latremouille-Viau D, Guerin A, Nitulescu R, Gagnon PS, Joseph GJ, Chen L
News
-
March 22, 2023
-
October 17, 2022
-
April 13, 2021
-
June 30, 2020